A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Completed · Phase 3 · NCT04615273
Conditions: Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
At a glance
- Research payments reported, 2025
- $3,437
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 264
About the trial
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Tested
- Lonapegsomatropin (drug), Placebo (other), Somatropin (drug)
- Dates
- Started 2020-12-03; completion 2023-12-01
- Results posted
- Yes
A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. A total of 264 adults (males and females) with growth hormone deficiency were included. Randomization occurred in a 1:1:1 ratio (lonapegsomatropin: placebo: daily somatropin product). This is a global trial conducted in, but not limited to, the United States, Europe, and Asia.
From ClinicalTrials.gov, last updated 2026-07-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ascendis Pharma Endocrinology Inc reported $3,437 in research payments for this study in 2025 (1 payments).
Products named: Skytrofa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Johns Hopkins University School of Medicine $3,437
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.